European House Dust Mite (Der p 7) IgE Test · Blood

If you have stubborn allergies, eczema, or asthma that doesn't seem to settle with standard treatment, the picture inside your immune system may be more layered than a basic dust mite test can show. House dust mite allergy isn't one thing. It's a reaction to a dozen different proteins inside the mite, and people who react to more of them tend to have more complex, harder-to-control disease.

This test looks at one of those proteins, called Der p 7 (a protein found in the gut and droppings of the European house dust mite). It's not the most common one your body reacts to, but when it shows up, it usually means your dust mite sensitivity has spread to multiple mite proteins, which carries different implications for severity, treatment choice, and response to allergy shots.

What This Test Actually Measures

Your blood is screened for IgE (immunoglobulin E, the antibody class that drives allergic reactions) directed specifically at the Der p 7 protein. This is different from a standard dust mite test, which measures IgE against a mixture of all mite proteins blended together. A general test tells you whether you react to mites. This one tells you whether you react to this particular piece of the mite.

Allergists call this kind of testing component-resolved diagnosis, meaning the test breaks the allergen down into its individual molecules and measures your antibody response to each one. The point is to get a molecular fingerprint of your allergy rather than a single yes-or-no answer.

Der p 7 is considered a mid-tier mite allergen. The most common targets your immune system reacts to are called Der p 1, Der p 2, and Der p 23. Der p 7 shows up less often but is rarely seen on its own. In one large study of mite-allergic patients in China, Der p 7 sensitization never appeared in isolation. It always came packaged with reactions to other mite proteins.

How Often Der p 7 Shows Up in Mite-Allergic People

Across studies, this antibody appears in a minority of dust mite-sensitized people, but the exact share varies a lot by geography and by what kind of allergic disease someone has.

Sources: Posa et al. 2017 (European birth cohort); Muddaluru et al. 2021 (multi-country comparison); González-Pérez et al. 2021 (atopic dermatitis cohort).

What this means for you: a positive Der p 7 result usually places you in a group with broader, more advanced mite sensitization. A negative result doesn't mean you aren't allergic to dust mites. It just means your immune system has focused its reaction on different mite proteins.

Why It Matters for Asthma and Allergic Rhinitis

People whose immune systems react to more mite proteins tend to have more allergic symptoms overall. In a long-term European cohort that followed 722 people from childhood into young adulthood, kids who developed antibodies to a wider range of mite proteins, including the mid-tier ones like Der p 7, had a higher risk of current mite-related hay fever and future asthma than kids who reacted to fewer mite proteins.

In children with mite-driven asthma compared to mite-allergic kids without asthma, the asthmatic children recognized more mite proteins and carried higher overall antibody levels. Der p 7 is one of the antibodies that tends to appear in this broader, more reactive pattern.

Why It Matters for Severe Eczema

Atopic dermatitis (the medical name for chronic eczema) is often driven by a strongly skewed immune response called Th2 inflammation, where the body overproduces allergic antibodies and inflammatory signals. In severe atopic dermatitis cohorts, Der p 7 antibodies appear frequently as part of a cluster of antibodies aimed at proteins found in mite droppings. People in this cluster tend to have more severe, harder-to-treat skin disease.

This matters because the standard biologic drug for severe eczema, dupilumab, works by quieting Th2 inflammation. Studies tracking patients on dupilumab for a year have shown measurable drops in mite-specific antibodies including Der p 7. The reading isn't a treatment target on its own, but it offers a window into whether your underlying allergic biology is shifting in response to therapy.

Why It Matters for Allergy Shots

Allergen immunotherapy (the long course of shots or under-the-tongue tablets used to retrain the immune system) is most often formulated around the two dominant mite proteins, Der p 1 and Der p 2. People whose mite allergy is mainly driven by these two proteins tend to respond best to conventional immunotherapy.

If your antibody profile also includes mid-tier proteins like Der p 7, standard immunotherapy may give weaker coverage of your specific allergic profile. This doesn't mean immunotherapy won't help you. It means your specialist may need to adjust expectations, monitor your response more carefully, or consider products that more fully cover your reactivity pattern. Knowing your Der p 7 status before starting a multi-year course of immunotherapy gives you and your clinician a more honest baseline.

An Exploratory Marker, Not a Verdict

There are no widely accepted numerical cutoffs for Der p 7 IgE that classify you as having mild, moderate, or severe allergy. Studies report mite component results in different ways, and a positive Der p 7 antibody in someone with no symptoms doesn't necessarily mean disease. This is a research-stage marker that adds nuance to a clinical picture, not a stand-alone diagnostic verdict.

It also doesn't replace the standard dust mite IgE test. Whole-extract mite testing captures your general sensitization to all mite proteins at once. The Der p 7 result is most informative as a layer on top of that broader number, particularly when symptoms or treatment responses don't match the basic test.

Tracking Your Trend

Specific IgE levels change over time. They can shift with sustained allergen exposure, immunotherapy, biologic medications like dupilumab, and the natural course of your allergic disease. A single reading is a snapshot. The trend is the story.

If you're starting allergy shots, beginning a biologic like dupilumab, or moving from a heavily mite-exposed environment to a cleaner one, getting a baseline now and a follow-up reading in six to twelve months gives you a way to measure whether the underlying biology is actually changing, not just whether your symptoms feel better that week. Studies of dupilumab show meaningful Der p 7 changes by 52 weeks. Studies of immunotherapy show that early antibody changes within the first months can hint at later treatment response.

Get a baseline reading. Recheck in six months if you're starting or finishing a treatment that should affect your allergy biology. Otherwise, retesting once a year while you're actively managing allergic disease is reasonable.

When Results Can Be Misleading

A few situations can shift your reading in ways that don't reflect your underlying allergy:

• Recent or ongoing immunotherapy: in the first months of dust mite allergy shots or sublingual tablets, mite-specific antibody levels often rise transiently before settling. A higher reading during this window isn't a sign that your allergy is worsening.
• Anti-IgE biologic medications: drugs like omalizumab and ligelizumab change how IgE behaves in your bloodstream and can affect total and specific IgE measurements without necessarily reflecting a change in your underlying allergic disease.
• Dupilumab treatment: this biologic gradually lowers many allergen-specific IgE levels including Der p 7. A drop on testing reflects the drug's secondary immune effect, not loss of your underlying allergy.
• Recent dust mite exposure intensity: changes in housing, climate, humidity, or mattress and bedding use can change your real allergen exposure and over time shift sensitization patterns. Short-term shifts within a few days are not well characterized.

What to Do With an Unexpected Result

A positive Der p 7 result on its own doesn't trigger a specific treatment change. It becomes useful in combination with other findings. If you also have a positive standard dust mite IgE test, positive results to other mite components like Der p 1, Der p 2, or Der p 23, ongoing symptoms despite avoidance measures, or severe atopic dermatitis, you have a clearer indication to see an allergist for full component-resolved testing and a discussion about whether immunotherapy or biologic treatment fits your profile.

If your Der p 7 result is positive but your standard mite test is negative, repeat the standard test and discuss the discrepancy with an allergist. The combination is uncommon and may reflect a measurement issue or an unusual sensitization pattern worth investigating. If your standard mite test is high but your Der p 7 is negative, your allergy is likely concentrated on the major mite proteins, which is actually favorable for conventional allergy shot response.